François Liebaert
Profile
François Liebaert served as the Chief Operating Officer & VP-Business Development at BioSystems International SAS.
Prior to that, he was the VP-Medical Affairs, Research & Devel at IntegraGen SA. He holds an MBA from École des Hautes Études Commerciales de Paris and a doctorate from Université de Lille II, which he received in 1985.
Former positions of François Liebaert
Companies | Position | End |
---|---|---|
BioSystems International SAS
BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Chief Operating Officer | - |
INTEGRAGEN | Chief Tech/Sci/R&D Officer | - |
Training of François Liebaert
Université de Lille II | Doctorate Degree |
École des Hautes Études Commerciales de Paris | Masters Business Admin |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
INTEGRAGEN | Health Services |
Private companies | 1 |
---|---|
BioSystems International SAS
BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Health Technology |
- Stock Market
- Insiders
- François Liebaert